Overview
Insights

Dipti assists corporate and university clients in drafting and prosecuting domestic and international patents in the biotechnology and pharmaceutical area. She also conducts patentability, freedom-to-operate, due diligence, and competitive landscape analyses. Dipti has extensive experience in handling and analyzing patent portfolio related to various inventions of molecular biology, immunology, microbiology, virology, pharmaceutical, and bioprocessing area.

Prior to joining the firm, Dipti worked as an in-house patent agent in Zydus Lifesciences Ltd., in India, where she effectively managed a diverse patent portfolio and conducted IP due diligence in safeguarding intellectual property of the organization for biologics.

Dipti assists corporate and university clients in drafting and prosecuting domestic and international patents in the biotechnology and pharmaceutical area. She also conducts patentability, freedom-to-operate, due diligence, and competitive landscape analyses. Dipti has extensive experience in handling and analyzing patent portfolio related to various inventions of molecular biology, immunology, microbiology, virology, pharmaceutical, and bioprocessing area.

Prior to joining the firm, Dipti worked as an in-house patent agent in Zydus Lifesciences Ltd., in India, where she effectively managed a diverse patent portfolio and conducted IP due diligence in safeguarding intellectual property of the organization for biologics.

Education

  • Gujarat University, Bachelor of Laws, 2016
  • Gujarat University, M.S., 2010, biotechnology
  • Gujarat University, B.S., 2008, biochemistry

Bar Admissions

  • U.S. Patent and Trademark Office (limited recognition)

Languages

  • Hindi
  • Gujarati
  • Co-inventor, “Antibodies to Human Programmed Death Receptor pd-1,” WO2021005546A1, January 14, 2021.
  • Registered Indian Patent Agent
  • Post-Graduate Diploma in Intellectual Property Rights (IPR), Indira Gandhi National Open University (IGNOU) and World Intellectual Property Organization (WIPO)